CLVLF Stock - Clinuvel Pharmaceuticals Limited
Unlock GoAI Insights for CLVLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $95.02M | $88.18M | $78.32M | $65.72M | $48.32M |
| Gross Profit | $79.14M | $80.45M | $69.53M | $55.24M | $43.26M |
| Gross Margin | 83.3% | 91.2% | 88.8% | 84.0% | 89.5% |
| Operating Income | $45.73M | $48.01M | $44.89M | $36.09M | $29.43M |
| Net Income | $36.17M | $35.64M | $30.60M | $20.88M | $24.73M |
| Net Margin | 38.1% | 40.4% | 39.1% | 31.8% | 51.2% |
| EPS | $0.72 | $0.72 | $0.62 | $0.42 | $0.50 |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Visit WebsiteEarnings History & Surprises
CLVLFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q3 2025 | Aug 27, 2025 | $0.18 | $0.29 | +55.4% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.13 | $0.17 | +29.0% | ✓ BEAT |
Q3 2024 | Aug 28, 2024 | $0.29 | $0.33 | +11.1% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.18 | $0.14 | -17.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.25 | $0.25 | +0.3% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $0.17 | $0.15 | -10.8% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $0.21 | $0.20 | -5.5% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | $0.17 | $0.08 | -51.3% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | — | $0.27 | — | — |
Q4 2020 | Dec 30, 2020 | $0.10 | $0.10 | -0.6% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | — | $0.21 | — | — |
Q4 2019 | Dec 30, 2019 | — | $0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $0.20 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.06 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.18 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.02 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.07 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.04 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.00 | — | — |
Latest News
Frequently Asked Questions about CLVLF
What is CLVLF's current stock price?
What is the analyst price target for CLVLF?
What sector is Clinuvel Pharmaceuticals Limited in?
What is CLVLF's market cap?
Does CLVLF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CLVLF for comparison